Partnership to advance Genomics research and healthcare innovation
The Department of Health–Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate of Abu Dhabi, and Novartis Middle East FZE today signed a Memorandum of Understanding to explore collaboration in genomics research, scientific capacity building, and advanced therapies, reinforcing their shared commitment to advancing healthcare innovation and improving patient outcomes.
The collaboration further strengthens Abu Dhabi’s genomics ecosystem by connecting global scientific expertise with one of the world’s largest population genomics programmes. The joint efforts in research, capability building and advanced therapies, will support the translation of genomic insights into improved health outcomes for patients in Abu Dhabi and around the world.
The partnership builds on Abu Dhabi’s leadership in genomics through the Emirati Genome Program, which has sequenced more than 900,000 genomes to date. These insights are creating new opportunities to advance precision medicine, support population-specific research and accelerate the development of more targeted approaches to prevention, diagnosis and treatment.
Scientific expertise
“By combining global scientific expertise with Abu Dhabi’s capabilities in genomics and precision medicine, we are accelerating the translation of research into solutions that can improve outcomes for patients and communities,” afirmed Dr. Asma Ibrahim Al Mannaei, Executive Director, Health Life Sciences Sector at the Department of Health–Abu Dhabi (DoH).
“We look forward to exploring initiatives that can contribute to better health outcomes and help address the evolving needs of patients in the UAE,” asserted Mohamed Ezz Eldin, Head of Novartis, GCC Cluster.
Collaboration
The MoU further reflects both organizations’ commitment to fostering scientific collaboration, strengthening local capabilities, and supporting innovation that can benefit patients in Abu Dhabi and beyond.
The Memorandum of Understanding was signed during a visit by the Department of Health – Abu Dhabi delegation to the Novartis Biomedical Research site in San Diego, held alongside BIO International Convention 2026, a press statement concluded.
